IonQ CRO Alameddine Rima sells $4.6m in shares
Azenta Inc. (NASDAQ:AZTA) reported its fiscal fourth quarter and full year 2025 results on November 21, 2025, highlighting solid revenue growth, significant margin expansion, and a strong cash position. The company’s stock surged 13.43% in pre-market trading following the announcement, reflecting positive investor sentiment.
Quarterly Performance Highlights
Azenta delivered Q4 2025 revenue of $159 million, representing 6% reported growth and 4% organic growth year-over-year, exceeding analysts’ expectations of $156.46 million. The company’s non-GAAP earnings per share reached $0.21, surpassing the forecasted $0.19 by 10.53%.
The Multiomics segment was a standout performer, achieving a record revenue quarter with 10% organic growth. Meanwhile, Sample Management Solutions, which accounts for 54% of total revenue, remained flat on an organic basis.
As shown in the following financial overview slide, Azenta demonstrated strong performance across key metrics:
"We are a stronger company today, operationally, culturally, and strategically," stated CEO John Marotta during the earnings call, emphasizing the company’s improved positioning.
Detailed Financial Analysis
For the full fiscal year 2025, Azenta reported revenue of $594 million, representing 4% reported growth and 3% organic growth compared to the previous year. The company achieved an adjusted EBITDA margin of 11.2% for the full year, delivering an impressive 310 basis points of margin expansion year-over-year.
The following slide breaks down Azenta’s operating performance for both Q4 and the full fiscal year:
The Q4 revenue breakdown reveals that Sample Management Solutions contributed $86 million (54% of total revenue), while Multiomics accounted for $73 million (46%). Within Sample Management Solutions, the company noted mid-single-digit growth in Sample Storage, offset by softness in Cryo Stores. The Multiomics segment showed particular strength with high-double-digit growth in Next Generation Sequencing, low-single-digit growth in Gene Synthesis, and 17% growth in China.
The revenue segment breakdown is illustrated in the following slide:
Financial Position
Azenta maintains a robust balance sheet with $546 million in cash and no outstanding debt, providing significant flexibility for future investments and strategic initiatives. This strong financial position supports the company’s long-term growth strategy and potential merger and acquisition activities.
"We are not in the freezer business. We are in the automated solutions business," emphasized CFO Lawrence Lin during the earnings call, highlighting the company’s strategic focus.
The company’s consolidated balance sheet shows $559 million in cash, cash equivalents, restricted cash, and marketable securities, including $13 million in current assets held for sale related to B Medical:
Free cash flow generation reached $38 million for the full fiscal year 2025, although the fourth quarter saw negative free cash flow of $6 million, which the company attributed to timing of revenue and milestone billings.
Forward-Looking Statements
Looking ahead to fiscal year 2026, Azenta provided guidance for organic revenue growth of 3% to 5% year-over-year, with low-single-digit growth expected in Multiomics and mid-single-digit growth projected for Sample Management Solutions.
The company anticipates approximately 300 basis points of adjusted EBITDA margin expansion and expects to improve free cash flow generation by over 30% compared to fiscal 2025.
As shown in the following guidance slide, Azenta also projects interest income of $16-18 million and a tax rate of 27-29% for fiscal 2026:
During the earnings call, management noted that they expect a slower start in the first half of fiscal 2026, with accelerated growth anticipated in the second half of the year. This projection takes into account potential challenges in the macro environment, including geopolitical uncertainties and government funding issues.
Strategic Initiatives
Azenta announced plans to host an Investor Day on December 10, 2025, at the company’s Indianapolis Biorepository. The event will highlight operations, growth priorities, longer-term financial framework, and capital allocation strategy.
The company’s strategic focus areas include automated solutions and potential mergers and acquisitions in Sample Repository Solutions, automated solutions, and synthesis. Management emphasized that these initiatives align with their long-term growth objectives and market positioning.
As summarized in the following slide, Azenta characterized 2025 as a transformative year and highlighted the momentum carrying into 2026:
Despite the positive outlook, the company acknowledged several challenges, including potential softness in capital expenditures affecting growth, market saturation in certain segments, and competitive pressures in the biotech industry. However, management expressed confidence in their strategic direction and ability to navigate these challenges while delivering on their financial targets.
With its strong financial position, margin improvement trajectory, and strategic focus on high-growth segments, Azenta appears well-positioned to continue its growth journey through fiscal 2026 and beyond.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.